Thursday 16 October, 2025
Introduction: Cancer is a complex disease and treatment success depends on tumour characteristics such as growth rate, immune cell infiltration, spatial…
Read moreAbstracts
A comparison of ordinary differential equation and agent-based approaches to PKPD modelling in oncology
Thursday 16 October, 2025
Introduction Mathematical models in oncology aid in the design of drugs and understanding of their mechanisms of action by simulation…
Read moreStochastic pharmacodynamics: Drug effects on the time to extinction of a heterogeneous tumour cell population
Thursday 16 October, 2025
Introduction: PK-PD models are often based on ordinary differential equations (ODEs) which are useful for ease of analysis but they…
Read moreEvaluation of extrapolation potential of IMPRES-M, a non-parametric Impulse-Response Modeling framework when applied to pharmacokinetic profiles of different dosing frequencies
Thursday 16 October, 2025
Introduction: Effective utilization of smoothing in pharmacokinetic (PK) and pharmacodynamic (PK-PD) modeling is limited as currently available approaches [1-4] cannot…
Read moreUse of informative prior distributions from mepolizumab data to support depemokimab PKPD model analysis
Thursday 16 October, 2025
Introduction: Depemokimab is an anti-IL-5 monoclonal antibody that blocks binding to the IL-5 receptor, leading to a rapid reduction of…
Read moreApplication of an immune-oncology framework to explore the role of regulatory T cells in antitumor response.
Thursday 16 October, 2025
Introduction and Objective: Regulatory T cell (Treg), characterized by the expression of Foxp3 intracellularly and CD25 at the surface, is…
Read moreRelationship between tumor growth and Treg activation status to optimize a previously published Immune oncology framework
Thursday 16 October, 2025
Introduction: The majority of the tumor growth inhibition models described inliterature evaluate the interplay between three major components: the growth…
Read moreSuccessful validation of a model-informed precision dosing instrument for meropenem in critically ill patients, the DoseCalculator, against NONMEM®
Thursday 16 October, 2025
Objectives: Model-informed precision dosing (MIPD) instruments can optimise antibiotic therapy by translating available clinical data to individualised dosing recommendations but…
Read moreQuantification of the difference in oral docetaxel pharmacokinetics in patients with prostate cancer compared to patients with other solid tumours
Thursday 16 October, 2025
Introduction: Oral docetaxel in combination with ritonavir boosting has been investigated for the treatment of solid tumours including prostate cancer…
Read moreExtrapolation of Phase 0 microdosing trials: a naïve pooled data modelling approach.
Thursday 16 October, 2025
Objectives: Microdosing is a method to predict pharmacokinetics of a therapeutic dose from microdose (max. 100 µg) data (1). The…
Read more